GANX

Gain Therapeutics Inc

Add to Watchlist

Advanced Chart

1.545

-0.125(-7.485%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.680

Open

1.680

VWAP

1.57

Vol

266.21K

Mkt Cap

53.41M

Low

1.535

Amount

416.75K

EV/EBITDA(TTM)

Total Shares

25.17M

49.09M

EV/OCF(TTM)

P/S(TTM)

Gain Therapeutics, Inc. is a biotechnology company. The Company is focused on developing novel small molecule therapeutics to treat diseases across several therapeutic areas, including, central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company’s drug discovery platform, Magellan discovers novel allosteric binding sites on proteins implicated in a disease and to identify proprietary small molecules that bind these sites to modulate protein function and treat the underlying cause of the disease. Its lead product candidate, GT-02287, is being developed for the treatment of GBA1 Parkinson’s disease, including restoration of glucocerebrosidase or GCase, function in the lysosome, reduction of toxic lipid substrates and toxic forms of alpha-synuclein, improved survival of dopaminergic neurons, and enhance in dopamine levels.

6 Analyst Rating

439.16% Upside

Wall Street analysts forecast GANX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GANX is 8.33 USD with a low forecast of 5.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

6 Buy

0 Hold

0 Sell

Strong Buy

439.16% Upside

Current: 1.545

Low

5.00

Averages

8.33

High

12.00

439.16% Upside

Current: 1.545

Low

5.00

Averages

8.33

High

12.00

Chardan Capital

Keay Nakae

Strong Buy

Maintains

2025-03-28

Reason

Chardan Capital

Keay Nakae

Price Target

2025-03-28

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2025-03-17

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2025-03-17

Reiterates

Strong Buy

Reason

Scotiabank

Louise Chen

Buy

Initiates

$12

2025-03-07

Reason

Scotiabank

Louise Chen

Price Target

$12

2025-03-07

Initiates

Buy

Reason

Roth MKM

Boobalan Pachaiyappan

Strong Buy

Maintains

2024-12-24

Reason

Roth MKM

Boobalan Pachaiyappan

Price Target

2024-12-24

Maintains

Strong Buy

Reason

Roth MKM keeps a Buy rating and $7 price target on Gain Therapeutics after the company received approval from Australian regulators to begin GT-02287 evaluation in Parkinson's disease patients. The firm believes that the Phase 1b study will deliver positive findings regarding safety, preliminary biochemical efficacy, and tolerability, the analyst tells investors in a research note.

Roth MKM

Boobalan Pachaiyappan

Strong Buy

Initiates

2024-12-05

Reason

Roth MKM

Boobalan Pachaiyappan

Price Target

2024-12-05

Initiates

Strong Buy

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Strong Buy

Reiterates

2024-11-25

Reason

HC Wainwright & Co.

Raghuram Selvaraju

Price Target

2024-11-25

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Gain Therapeutics Inc (GANX.O) is -2.61, compared to its 5-year average forward P/E of -3.12. For a more detailed relative valuation and DCF analysis to assess Gain Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-3.12

Current PE

-2.61

Overvalued PE

-1.78

Undervalued PE

-4.45

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

2622.70

Current PS

1016.41

Overvalued PS

10469.69

Undervalued PS

-5224.28